Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florent Grange

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Archives of Dermatology|June 19, 2008
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndromeGaëlle Quereux, Sonia Marques, Jean-Michel Nguyen, et al.
Dermatology and Therapy|September 24, 2021
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629Brett G M Hughes, Rene Gonzalez Mendoza, Nicole Basset-Seguin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2022
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Caroline Robert, Jean-Jacques Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2021
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saiag, Caroline Robert, Jean-Jacques Grob, et al.
Cancer Research|January 31, 2016
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF HeterodimerizationLise Boussemart, Isabelle Girault, Hélène Malka-Mahieu, et al.
Archives of Dermatology|May 21, 2008
Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in FranceFlorent Grange, Fabien Vitry, Florence Granel-Brocard, et al.
Archives of Dermatology|September 19, 2007
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 casesFlorent Grange, Marie Beylot-Barry, Phillipe Courville, et al.
Dermatology and Therapy|November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.
Blood|January 17, 2004
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomasFlorent Grange, Tony Petrella, Marie Beylot-Barry, et al.
Journal of the American Academy of Dermatology|February 22, 2024
Real-life practice of reflectance confocal microscopy in France: A prospective multicenter studyMarion Stefanski, Aurore Le Guern, Laetitia Visseaux, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Archives of Dermatology|June 19, 2008
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndromeGaëlle Quereux, Sonia Marques, Jean-Michel Nguyen, et al.
Dermatology and Therapy|September 24, 2021
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629Brett G M Hughes, Rene Gonzalez Mendoza, Nicole Basset-Seguin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2022
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Caroline Robert, Jean-Jacques Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2021
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saiag, Caroline Robert, Jean-Jacques Grob, et al.
Cancer Research|January 31, 2016
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF HeterodimerizationLise Boussemart, Isabelle Girault, Hélène Malka-Mahieu, et al.
Archives of Dermatology|May 21, 2008
Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in FranceFlorent Grange, Fabien Vitry, Florence Granel-Brocard, et al.
Archives of Dermatology|September 19, 2007
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 casesFlorent Grange, Marie Beylot-Barry, Phillipe Courville, et al.
Dermatology and Therapy|November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.
Blood|January 17, 2004
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomasFlorent Grange, Tony Petrella, Marie Beylot-Barry, et al.
Journal of the American Academy of Dermatology|February 22, 2024
Real-life practice of reflectance confocal microscopy in France: A prospective multicenter studyMarion Stefanski, Aurore Le Guern, Laetitia Visseaux, et al.
Pageof 8